注射用米铂制剂配方与冻干工艺研究

目的 研究注射用米铂的配方及冻干生产工艺。方法 通过冻干溶剂的选择、原料溶解度试验、处方筛选、预冻工艺研究等确定注射用米铂配方和冻干工艺参数的控制范围。结果 确定冻干溶剂采用叔丁醇和环己烷的混合溶剂,环己烷最佳比例范围为10%~30%,药物浓度最佳范围为5~25 mg·mL^-1,确定冻干工艺采用阶段性预冻方式。结论 选定的配方和工艺可行,自研制剂与参比制剂质量等同,节约了工艺生产成本。     

HPLC法测定米铂白蛋白结合型纳米制剂中米铂的含量

目的 建立米铂白蛋白结合型纳米制剂中米铂含量测定的高效液相色谱(HPLC)法.方法 采用HPLC测定米铂白蛋白结合型纳米制剂中米铂的含量.色谱条件:辛烷基硅烷键合硅胶色谱柱(250 mm×4.6 mm,5μm),甲醇-乙腈-水(91:1:8)洗脱,流速1.0 ml/min,检测波长210 nm,柱温30℃,进样量20μ...     

铂类抗肿瘤药物米铂的合成及结构表征

目的:合成抗肿瘤新药米铂。方法:以顺式-(1R,2R)-1,2-环己二胺-二碘合铂(环铂)、硝酸银、正十四碳酸、氢氧化钠为原料合成米铂,采用元素分析、质谱、红外光谱、核磁共振氢谱和热分析对其结构进行表征。结果:合成的化合物结构与标题化合物一致,产率约73%。结论:该方法便于操作,产率高,适合进一步研究。     

Prospective,randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma

Aim

Transcatheter arterial chemoembolization (TACE) has been recognized as a treatment option for patients with intermediate hepatocellular carcinoma (HCC). This randomized, controlled study compared the local control efficacy of TACE with miriplatin (platinum monohydrate) or with epirubicin.

Methods

The study group consisted of 200 Japanese patients with unresectable HCC treated at the Kitasato University East Hospital (Sagamihara, Japan) between July 2010 and June 2013. The primary end‐point of the study was time to tumor progression (TTP).

Results

We analyzed 198 patients (99 in the miriplatin group and 99 in the epirubicin group) treated with TACE. The median TTP in the epirubicin group was 5.9 months (95% confidence interval [CI], 4.8–7.0) and 7.6 months (95% CI, 5.8–9.4) in the miriplatin group. There was a significant difference between the two groups (P = 0.021; risk ratio, 1.488; 95% CI: 1.061–2.086). In the epirubicin group, 53 patients (53%) had complete response, 24 patients (24%) had partial response, 12 patients (12%) had stable disease, and 10 patients (10%) had progressive disease. In the miriplatin group, 38 patients (38%) had complete response, 41 patients (41%) had partial response, 2 patients (2%) had stable disease, and 18 patients (18%) had progressive disease. There was no significant difference in the response rate (P = 0.862). Overall incidences of adverse events and adverse drug reactions did not differ significantly between the two groups.

Conclusion

Miriplatin proved more effective than epirubicin in TACE for unresectable HCC. The trial described in this work has been registered under the trial number: UMIN000004790.